88 related articles for article (PubMed ID: 26833163)
1. Global Urine Metabolomics in Patients Treated with First-Line Tuberculosis Drugs and Identification of a Novel Metabolite of Ethambutol.
Das MK; Arya R; Debnath S; Debnath R; Lodh A; Bishwal SC; Das A; Nanda RK
Antimicrob Agents Chemother; 2016 Apr; 60(4):2257-64. PubMed ID: 26833163
[TBL] [Abstract][Full Text] [Related]
2. Urinary drug metabolite profiling of tuberculosis treatment failure using proton nuclear magnetic resonance.
Opperman M; Mason S; van der Westhuizen J; Loots DT; du Preez I
J Pharm Biomed Anal; 2024 Jun; 248():116297. PubMed ID: 38906071
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of a UPLC-MS/MS Method for Therapeutic Drug Monitoring, Pharmacokinetic and Stability Studies of First-Line Antituberculosis Drugs in Urine.
Abouzid M; Kosicka-Noworzyń K; Karaźniewicz-Łada M; Rao P; Modi N; Xie YL; Heysell SK; Główka A; Kagan L
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257250
[TBL] [Abstract][Full Text] [Related]
4. Urinary biomarkers of mycobacterial load and treatment response in pulmonary tuberculosis.
Xia Q; Lee MH; Walsh KF; McAulay K; Bean JM; Fitzgerald DW; Dupnik KM; Johnson WD; Pape JW; Rhee KY; Isa F
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32809976
[TBL] [Abstract][Full Text] [Related]
5. Point-of-care Arkansas method for measuring adherence to treatment with isoniazid.
Guerra RL; Conde MB; Efron A; Loredo C; Bastos G; Chaisson RE; Golub JE
Respir Med; 2010 May; 104(5):754-7. PubMed ID: 20202806
[TBL] [Abstract][Full Text] [Related]
6. A validated liquid chromatography-tandem mass spectrometry assay for the analysis of isoniazid and its metabolite acetyl-isoniazid in urine.
Maputla SP; Van Dalen W; Joubert A; Norman J; Castel S; van der Merwe M; Wiesner L
J Mass Spectrom Adv Clin Lab; 2024 Apr; 32():11-17. PubMed ID: 38356778
[TBL] [Abstract][Full Text] [Related]
7. The reliability and practicality of the Arkansas method assay of isoniazid adherence.
Schmitz KE; Hovell MF; Wong CA; Kelley NJ; Nilsen D; Blumberg EJ; Hill LL; Sipan CL; Kolody B; Chatfield DA
Clin Nurs Res; 2010 May; 19(2):131-43. PubMed ID: 20435784
[TBL] [Abstract][Full Text] [Related]
8. The identification of key metabolites and mechanisms during isoniazid/rifampicin-induced neurotoxicity and hepatotoxicity in a mouse model by HPLC-TOF/MS-based untargeted urine metabolomics.
Song Y; Ma J; Gao H; Zhai J; Zhang Y; Gong J; Qu X; Hu T
J Pharm Biomed Anal; 2023 Nov; 236():115709. PubMed ID: 37690188
[TBL] [Abstract][Full Text] [Related]
9. Pyrazinamide-induced hepatotoxicity and gender differences in rats as revealed by a
Zhao H; Si ZH; Li MH; Jiang L; Fu YH; Xing YX; Hong W; Ruan LY; Li PM; Wang JS
Toxicol Res (Camb); 2017 Jan; 6(1):17-29. PubMed ID: 30090474
[TBL] [Abstract][Full Text] [Related]
10. Chromatographic Methods for the Determination of Rifampicin, Isoniazid, Pyrazinamide, Ethambutol, and Main Metabolites in Biological Samples: A Review.
Brozyna-Heredia IY; Ganoza-Yupanqui ML; Moreno-Exebio L; Dos Santos JL
Crit Rev Anal Chem; 2022 Nov; ():1-16. PubMed ID: 36444713
[TBL] [Abstract][Full Text] [Related]
11. Editorial for special issue: Metabolomics in India.
Misra BB; Volmer DA
Anal Sci Adv; 2021 Dec; 2(11-12):495-496. PubMed ID: 38715857
[No Abstract] [Full Text] [Related]
12. Metabolomics biomarkers for tuberculosis diagnostics: current status and future objectives.
Preez ID; Luies L; Loots DT
Biomark Med; 2017 Feb; 11(2):179-194. PubMed ID: 28097879
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Accuracy of the Small Membrane Filtration Method for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Prevalence Setting.
Boum Y; Kim S; Orikiriza P; Acuña-Villaorduña C; Vinhas S; Bonnet M; Nyehangane D; Mwanga-Amumpaire J; Fennelly KP; Jones-López EC
J Clin Microbiol; 2016 Jun; 54(6):1520-1527. PubMed ID: 27030493
[TBL] [Abstract][Full Text] [Related]
14. MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration.
Stinson K; Kurepina N; Venter A; Fujiwara M; Kawasaki M; Timm J; Shashkina E; Kreiswirth BN; Liu Y; Matsumoto M; Geiter L
Antimicrob Agents Chemother; 2016 Jun; 60(6):3316-22. PubMed ID: 26976868
[TBL] [Abstract][Full Text] [Related]
15. Systems Biology Approaches for Host-Fungal Interactions: An Expanding Multi-Omics Frontier.
Culibrk L; Croft CA; Tebbutt SJ
OMICS; 2016 Mar; 20(3):127-38. PubMed ID: 26885725
[TBL] [Abstract][Full Text] [Related]
16. Macrophage global metabolomics identifies cholestenone as host/pathogen cometabolite present in human Mycobacterium tuberculosis infection.
Chandra P; Coullon H; Agarwal M; Goss CW; Philips JA
J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 35104812
[TBL] [Abstract][Full Text] [Related]
17. Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin.
Combrink M; Loots DT; du Preez I
Toxicol Lett; 2020 Apr; 322():104-110. PubMed ID: 31981687
[TBL] [Abstract][Full Text] [Related]
18. Cancer metabolites: promising biomarkers for cancer liquid biopsy.
Wang W; Rong Z; Wang G; Hou Y; Yang F; Qiu M
Biomark Res; 2023 Jun; 11(1):66. PubMed ID: 37391812
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic analysis of Mycobacterium tuberculosis reveals metabolic profiles for identification of drug-resistant tuberculosis.
Chaiyachat P; Kaewseekhao B; Chaiprasert A; Kamolwat P; Nonghanphithak D; Phetcharaburanin J; Sirichoat A; Ong RT; Faksri K
Sci Rep; 2023 May; 13(1):8655. PubMed ID: 37244948
[TBL] [Abstract][Full Text] [Related]
20. Biomarker discovery for tuberculosis using metabolomics.
Yu Y; Jiang XX; Li JC
Front Mol Biosci; 2023; 10():1099654. PubMed ID: 36891238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
